IMM · ASX

Immutep Ltd (ASX:IMM)

AU$0.32

 -0.005 (-1.562%)
ASX:Live
15/10/2024 04:10:23 PM
Hammer Bearish HALO Small HALO Ords HALO Consensus Value GROWTH AUS +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

IMM Overview

IMM Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Very Strong

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About IMM

Website

Immutep Ltd

Telephone

61.2.8315.7003

Address

Level 32, Suite 32.07 264 George Street Australia Square Sydney, New South Wales (NSW) 2000

Description

N/A

IMM Price Chart

Key Stats

Market Cap

AU$465.46M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.23 - 0.48

Trade Value (12mth)

AU$266,394.00

1 week

1.59%

1 month

-20%

YTD

-6.39%

1 year

21.87%

All time high

4.07

Key Fundamentals

EPS 3 yr Growth

-27.30%

EBITDA Margin

N/A

Operating Cashflow

-$35m

Free Cash Flow Return

-21.20%

ROIC

-26.00%

Interest Coverage

-1,573.40

Quick Ratio

18.20

Other Data

Shares on Issue (Fully Dilluted)

1216m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

1.21

IMM Announcements

Latest Announcements

Date Announcements

14 October 24

Appendix 3Z - Anne Anderson

×

Appendix 3Z - Anne Anderson

10 October 24

2024 AGM & Key Dates

×

2024 AGM & Key Dates

04 October 24

Resignation of Non-executive Director

×

Resignation of Non-executive Director

03 October 24

Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed

×

Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed

02 October 24

Change of Director's Interest Notice - Pete Meyers

×

Change of Director's Interest Notice - Pete Meyers

01 October 24

Application for quotation of securities - IMM

×

Application for quotation of securities - IMM

26 September 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

25 September 24

Change in substantial holding from IFL

×

Change in substantial holding from IFL

24 September 24

Immutep receives A$3.6 million French R&D Tax Incentive

×

Immutep receives A$3.6 million French R&D Tax Incentive

24 September 24

Change in substantial holding

×

Change in substantial holding

19 September 24

Change of Director's Interest Notice - M Voigt

×

Change of Director's Interest Notice - M Voigt

18 September 24

Data to be presented from Ph II trial in Soft Tissue Sarcoma

×

Data to be presented from Ph II trial in Soft Tissue Sarcoma

16 September 24

New Positive Efficacy Data for Efti in Head and Neck Cancer

×

New Positive Efficacy Data for Efti in Head and Neck Cancer

12 September 24

Becoming a substantial holder

×

Becoming a substantial holder

06 September 24

S&P DJI Announces September 2024 Quarterly Rebalance

×

S&P DJI Announces September 2024 Quarterly Rebalance

30 August 24

Appendix 4E & 2024 Full Year Statutory Accounts

×

Appendix 4E & 2024 Full Year Statutory Accounts

21 August 24

Immutep Corporate Presentation

×

Immutep Corporate Presentation

20 August 24

TACTI-003 data selected for oral presentation at ESMO 2024

×

TACTI-003 data selected for oral presentation at ESMO 2024

14 August 24

First Participant Dosed in Phase I Study of IMP761

×

First Participant Dosed in Phase I Study of IMP761

07 August 24

Immutep to Participate in Upcoming Investor Conferences

×

Immutep to Participate in Upcoming Investor Conferences

31 July 24

Immutep Quarterly Activities Report and Appendix 4C

×

Immutep Quarterly Activities Report and Appendix 4C

26 July 24

Change in substantial holding

×

Change in substantial holding

22 July 24

Successful Meeting with FDA on Phase III Design in NSCLC

×

Successful Meeting with FDA on Phase III Design in NSCLC

17 July 24

Regulatory Clearance received for Phase 1 trial of IMP761

×

Regulatory Clearance received for Phase 1 trial of IMP761

12 July 24

Webcast to discuss data presented at ESMO Plenary Session

×

Webcast to discuss data presented at ESMO Plenary Session

IMM Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.04 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock 24.5 -19.7 19.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.04 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -58.2 6.6 11.4 Lock Lock Lock
     Yield % Lock Lock Lock Lock -12.3 -12.6 -9.8 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.11 0.11 0.13 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.09 0.11 0.12 Lock Lock Lock
     Growth % Lock Lock Lock Lock 19.4 12.7 17.8 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 870 901 1,201 Lock Lock Lock
Basic m Lock Lock Lock Lock 870 901 1,201 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -100.0 N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 36 43 48 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 8.6 -8.9 -9.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,111.2 N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 1,211 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -36 -43 -48 Lock Lock Lock
     Growth % Lock Lock Lock Lock -69.3 -18.1 -12.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -21,317.2 N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -38 -45 -50 Lock Lock Lock
     Growth % Lock Lock Lock Lock -63.2 -17.1 -12.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -22,528.4 N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -32 -40 -43 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -32 -40 -43 Lock Lock Lock
     Growth % Lock Lock Lock Lock -7.7 -23.9 -7.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -18,906.5 N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -30 -35 -35 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 -21 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 50 76 95 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -30 -35 -35 Lock Lock Lock
     Growth % Lock Lock Lock Lock -71.3 -17.1 1.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -177.6 N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 80 123 182 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 102 147 202 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 2 1 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -78 -122 -180 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 8 11 12 Lock Lock Lock
Equity $m Lock Lock Lock Lock 94 136 190 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 96 138 191 Lock Lock Lock
     Growth % Lock Lock Lock Lock 26.0 43.8 38.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -31.5 -27.1 -21.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -34.2 -29.2 -22.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -44.7 -38.5 -30.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -37.6 -34.2 -26.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -35.2 -30.3 -21.2 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -392.9 -2,101.6 -1,573.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.2 2.8 3.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -83.2 -89.5 -95.1 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 14.2 13.8 18.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 14.2 13.8 18.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 88.1 91.4 95.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -471.3 -361.8 -332.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 1,682.3 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -18,906.5 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -31.5 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -31.5 -27.1 -21.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -34.2 -29.2 -22.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -34.2 -29.2 -22.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 15,530.4 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 15,530.4 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 414.9 735.9 745.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 15,115.5 -735.9 -745.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

1.21%

Value ($M)

5

Prior Change

N/A

7 Day Change

0.10%

1 Month Change

1.00%

3 Month Change

1.00%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IMM Shortsell

Frequently Asked Questions

The current share price of Immutep Ltd (IMM:ASX) is AU$0.32.
The 52-week high share price for Immutep Ltd (IMM:ASX) is AU$0.48.
The 52-week low share price for Immutep Ltd (IMM:ASX)? is AU$0.23.
Immutep Ltd (IMM:ASX) does not pay a dividend.
Immutep Ltd (IMM:ASX) does not pay a dividend.
Immutep Ltd (IMM:ASX) has a franking level of 0.0%.
Immutep Ltd (IMM:ASX) is classified in the Healthcare.
The current P/E ratio for Immutep Ltd (IMM:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.